Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Mayar Capital Abdulaziz A. Alnaim | “Croda International. Founded: 1925. In 1925, two men named Crowe and Dawe set up business in a disused waterworks at Rawcliffe Bridge, a hamlet in the flat farmland of East Yorkshire, with the aim of extracting lanolin — a waxy grease — from raw sheep's wool. Croda is not a household name, and deliberately so. It sells not to consumers but to the companies that serve them, and its ingredients form a small but vital part of other people's products. Croda's ingredients might be found in a vaccine injection that must keep the active molecules intact, a beauty brand's anti-ageing moisturiser, or in a crop spray that clings to leaves instead of washing away in the rain. The economics are attractive: the ingredient is typically a tiny fraction of the customer's cost base, yet central to the performance and marketing claims of the finished product. That combination — low cost to the buyer, high value to the brand — is the source of Croda's pricing power, and has historically delivered gross margins above 40% and returns on capital well into the teens. Having ridden a surge of pandemic-era demand, Croda suffered a sharp reversal as customers ran down inventories, the agricultural cycle turned, and a build-up of cost met falling volumes. Utilisation fell well below historic levels and the operating margin, once flirting with the mid-twenties, compressed towards the mid-teens. 2025 saw sales begin to recover, but margins are still well below historic levels. We think that gap looks more cyclical than structural. A new framework targets 3–6% annual growth to 2028, a margin above 20% and a return on capital of at least 10%, with some £100m of cost savings; with the heavy investment phase complete and the share of sales from new and protected products — Croda's measure of genuine innovation and most important driver of gross margins — still climbing, we believe margins can recover towards, and perhaps beyond, 20%. Croda's recovery will not be linear, and patience will be required. But we are buying a century-old company, with deep customer relationships and genuine innovation, at a depressed point in its cycle and a modest multiple of earnings.” | NEUTRAL | Q2 2026 Jul 25, 2026 | View Pitch |
Mayar Capital Abdulaziz A. Alnaim | “Croda International is a specialty chemicals provider whose high-value ingredients represent a small portion of customer costs but are vital to performance, granting the firm strong pricing power. Although a cyclical inventory correction and downturn in agricultural markets have temporarily depressed asset utilization and margins, these issues appear cyclical rather than structural. Buying this century-old innovator at a depressed valuation point offers an highly attractive risk-reward profile.” | BULL | Q2 2026 Jul 3, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
